Bivin & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bivin & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	–	–	352
2021 Q4	$0	Buy	+10	New	+$237	﹤0.01%	396

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bivin & Associates's AUPH Position: Q1 2022 in Review

Bivin & Associates sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 10 shares.

Bivin & Associates first reported a position in AUPH in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

Bivin & Associates reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 10 Aurinia Pharmaceuticals shares in Q1 2022.
Bivin & Associates first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Bivin & Associates's Aurinia Pharmaceuticals position peaked at $0 in Q4 2021.
184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.